Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | CHUK | O15111 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.59 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | MARK3 | P27448 | 1/20 | 0.59 |
| ▸ | AKT1 | P31749 | 1/20 | 0.59 |
| ▸ | AKT2 | P31751 | 1/20 | 0.59 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11989630 | 1.00 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL18286844 | 0.96 | CHEK1 (0.56) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989635 | 0.96 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL12201344 | 0.96 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6150586 | 0.96 | PLK4 (0.63) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356576 | 0.95 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| Semapimod SCHEMBL6356573 | 0.95 | PLK4 (0.62) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL11989623 | 0.95 | PLK4 (0.64) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL13248987 | 0.93 | PLK4 (0.59) | PLK4CHEK1AURKACHUKDAPK3 | |
| SCHEMBL24681759 | 0.92 | PLK4 (0.58) | PLK4CHEK1AURKACHUKDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2543661-B1 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING BV (NL) | 2016-12-07 | — | — | EP | disclosed |
| EP-1778265-B1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | FERRING BV (NL) | 2013-04-24 | — | — | EP | disclosed |
| US-8247455-B2 | Guanylhydrazone compounds, compositions, methods of making and using | FERRING B.V. (NL) | 2012-08-21 | — | — | US | disclosed |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863334-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | CYTOKINE PHARMASCIENCES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291647-B2 | Guanylhydrazone compounds, compositions, methods of making and using | CYTOKINE PHARMASCIENCES, INC. (US) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070959-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | PLK4 3203/4885CHEK1 2702/4885AURKA 3086/4885 |
| US-20110144189-A1 | GUANYLHYDRAZONE COMPOUNDS, COMPOSITIONS, METHODS OF MAKING AND USING | GMPS, GANC, GLO1 | PLK4 3203/4885CHEK1 2702/4885AURKA 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.